NASDAQ:INCR

InterCure (INCR) Stock Forecast, Price & News

$1.65

-0.02 (-1.20%)

(As of 09/20/2023 ET)

Compare

Today's Range: $1.65
▼
$1.70
50-Day Range: $1.39
▼
$1.72
52-Week Range: $1.39
▼
$5.56

Volume: 25,619 shs
Average Volume: 44,491 shs
Market Capitalization: N/A

P/E Ratio: 12.69
Dividend Yield: N/A
Price Target: $5.00

InterCure MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 203.0% Upside
$5.00 Price Target
Short Interest: Healthy
0.13% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
InterCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, InterCure has a forecasted upside of 203.0% from its current price of $1.65.
Amount of Analyst Coverage
InterCure has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.13% of the float of InterCure has been sold short.
Short Interest Ratio / Days to Cover
InterCure has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in InterCure has recently increased by 156.62%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
InterCure does not currently pay a dividend.
Dividend Growth
InterCure does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INCR.

1.7

News and Social Media Coverage

News Sentiment
InterCure has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.
Search Interest
2 people have searched for INCR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
3 people have added InterCure to their MarketBeat watchlist in the last 30 days.

N/A

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, InterCure insiders have not sold or bought any company stock.

1.9

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of InterCure is 12.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.94.
Price to Earnings Ratio vs. Sector
The P/E ratio of InterCure is 12.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 159.19.
Price to Book Value per Share Ratio
InterCure has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About InterCure (NASDAQ:INCR) Stock

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

INCR Price History

30 days | 90 days | 365 days | Advanced Chart

INCR Stock News Headlines

September 1, 2023 | benzinga.com

Canndoc Reports Record Revenue Amid Cannabis Market Turmoil

August 22, 2023 | theglobeandmail.com

Closing Bell: Intercure Ltd up on Monday (INCR-U)

September 21, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

August 19, 2023 | theglobeandmail.com

ul: Bottom 25 Performing Stocks Year-to-Date on TSX (INCR-U)

August 3, 2023 | msn.com

InterCure: Leader In Israel's Growing Medical Cannabis Market

July 23, 2023 | theglobeandmail.com

Intercure: Top 10 Undervalued Micro Cap Stocks on TSX (INCR-U)

July 10, 2023 | financialpost.com

InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE

May 16, 2023 | finanznachrichten.de

InterCure Ltd.: InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY

September 21, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

May 16, 2023 | msn.com

InterCure Stock Trading Lower On Q1 Revenue Growth Of 22%, Here Are The Details

May 15, 2023 | benzinga.com

InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY

April 27, 2023 | theglobeandmail.com

Closing Bell: Intercure Ltd down on Monday (INCR-U)

April 26, 2023 | theglobeandmail.com

Closing Bell: Intercure Ltd flat on Monday (INCR-U)

April 25, 2023 | finance.yahoo.com

InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary

April 24, 2023 | finance.yahoo.com

InterCure Informs That An Application To Approve a Class Action Against 26 Cannabis Companies in Israel, Including InterCure, Was Filed to The Court In Israel

April 20, 2023 | finance.yahoo.com

InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries

April 19, 2023 | theglobeandmail.com

Closing Bell: Intercure Ltd flat on Friday (INCR-U)

April 15, 2023 | theglobeandmail.com

Closing Bell: Intercure Ltd down on Friday (INCR-U)

April 11, 2023 | theglobeandmail.com

Closing Bell: Intercure Ltd flat on Wednesday (INCR-U)

April 8, 2023 | theglobeandmail.com

Closing Bell: Intercure Ltd down on Wednesday (INCR-U)

April 3, 2023 | finance.yahoo.com

InterCure Reschedules 2022 Full Year Results Conference Call

April 3, 2023 | msn.com

InterCure Shares Soar On FY22 Record Revenue Of $108.3M

April 1, 2023 | theglobeandmail.com

Closing Bell: Intercure Ltd up on Thursday (INCR-U)

March 31, 2023 | finance.yahoo.com

InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results

March 30, 2023 | theglobeandmail.com

Intercure: Bottom 25 Performing Stocks Year-to-Date on TSX (INCR-U)

March 16, 2023 | money.usnews.com

Intercure Ltd

February 14, 2023 | msn.com

InterCure Sues Cann Pharmaceuticals To Recover Funds Following Failed Merger

See More Headlines

Receive INCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InterCure and its competitors with MarketBeat's FREE daily newsletter.

INCR Company Calendar

Today: 9/20/2023
Next Earnings (Estimated): 11/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Drug Manufacturers—Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INCR
CUSIP: N/A
CIK: 1857030
Web: www.intercure.co
Phone: 972774605012
Fax: N/A
Employees: 370
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +203.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.13
Trailing P/E Ratio: 12.69
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $13.36 million
Net Margins: 4.28%
Pretax Margin: 6.32%
Return on Equity: 3.37%
Return on Assets: 1.98%

Debt

Debt-to-Equity Ratio: 0.20
Current Ratio: 1.90
Quick Ratio: 1.21

Sales & Book Value

Annual Sales: $115.83 million
Price / Sales: N/A
Cash Flow: $0.38 per share
Price / Cash Flow: 4.31
Book Value: $3.64 per share
Price / Book: 0.45

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 1.03

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Alexander Rabinovitch (Age 52)
CEO & Director

Mr. Amos Cohen (Age 44)
Chief Financial Officer

Einat Zehavi
VP of Sales

Mr. Rami Levy (Age 58)
Chief Operating Officer of Canndoc

Mr. Omri Batzir
Corp. Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

INCR Stock - Frequently Asked Questions

Should I buy or sell InterCure stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InterCure in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INCR shares.
View INCR analyst ratings or view top-rated stocks.
What is InterCure's stock price forecast for 2023?: 1 Wall Street analysts have issued twelve-month price targets for InterCure's stock. Their INCR share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 203.0% from the stock's current price.
View analysts price targets for INCR or view top-rated stocks among Wall Street analysts.
How have INCR shares performed in 2023?: InterCure's stock was trading at $3.30 at the beginning of the year. Since then, INCR stock has decreased by 50.0% and is now trading at $1.65.
View the best growth stocks for 2023 here.
Are investors shorting InterCure?: InterCure saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 34,900 shares, an increase of 156.6% from the August 15th total of 13,600 shares. Based on an average daily volume of 46,500 shares, the short-interest ratio is presently 0.8 days. Currently, 0.1% of the company's shares are short sold.
View InterCure's Short Interest.
When is InterCure's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our INCR earnings forecast.

What is InterCure's stock symbol?: InterCure trades on the NASDAQ under the ticker symbol "INCR."
Who are InterCure's major shareholders?: InterCure's stock is owned by many different institutional and retail investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (1.20%), Cambria Investment Management L.P. (0.14%) and Citadel Advisors LLC (0.00%).
How do I buy shares of InterCure?: Shares of INCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is InterCure's stock price today?: One share of INCR stock can currently be purchased for approximately $1.65.
How many employees does InterCure have?: The company employs 370 workers across the globe.
How can I contact InterCure?: The official website for the company is www.intercure.co. The company can be reached via phone at 972774605012.

This page (NASDAQ:INCR) was last updated on 9/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial